Introduction:
The HEART Pathway is a diagnostic protocol designed to identify low-risk patients presenting to the emergency department with chest pain that are safe for early discharge. This protocol has been shown to significantly decrease health care resource utilization compared with usual care. However, the impact of the HEART Pathway on the cost of care has yet to be reported.
Methods and Results:
We performed a cost analysis of patients enrolled in the HEART Pathway trial, which randomized participants to either usual care or the HEART Pathway protocol. For low-risk patients, the HEART Pathway recommended early discharge from the emergency department without further testing. We compared index visit cost, cost at 30 days, and cardiac-related health care cost at 30 days between the 2 treatment arms. Costs for each patient included facility and professional costs. Cost at 30 days included total inpatient and outpatient costs, including the index encounter, regardless of etiology. Cardiac-related health care cost at 30 days included the index encounter and costs adjudicated to be cardiac-related within that period. Two hundred seventy of the 282 patients enrolled in the trial had cost data available for analysis. There was a significant reduction in cost for the HEART Pathway group at 30 days (median cost savings of $216 per individual), which was most evident in low-risk (Thrombolysis In Myocardial Infarction score of 0-1) patients (median savings of $253 per patient) and driven primarily by lower cardiac diagnostic costs in the HEART Pathway group. Conclusions: Using the HEART Pathway as a decision aid for patients with undifferentiated chest pain resulted in significant cost savings.
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Chest pain is one of the most common symptoms evaluated in the emergency department (ED). One of the primary diagnostic concerns during this evaluation is whether there is evidence of an acute coronary syndrome (ACS) because this diagnosis is a major cause of short-and long-term morbidity and mortality. The cost of chest pain evaluations has been estimated at $10 billion annually, yet only 10% of these patients are ultimately diagnosed as having ACS or other acute diagnoses requiring urgent hospitalization, resulting in very inefficient health care resource utilization [1, 2] .
In an effort to improve the efficiency of evaluating this patient group, our group recently validated a risk stratification tool called the HEART Pathway, which uses the HEART score combined with a serial troponins at 0 and 3 hours after ED presentation [3] . In a randomized trial, the HEART Pathway was shown to reliably categorize ED patients who presented with acute, undifferentiated chest pain as high risk (≥1%) or low risk (b1%) for major adverse cardiovascular events (MACEs) at 30 days. Compared with usual care, use of the HEART Pathway significantly decreased objective cardiac testing at 30 days by 12.1% (68.8% vs 56.7%; P = .04) and length of stay by 12 hours (9.9 vs 21.9 hours; P = .01) and increased early discharges by 21.3% (39.7% vs 18.4%; P b .01). None of the patients identified for early discharge had major adverse cardiac events within 30 days [3] . However, the impact of the HEART Pathway on cost, compared with usual care, has yet to be reported. Based on our prior studies, we hypothesized that there will be cost American Journal of Emergency Medicine 35 (2017) 77-81 ☆ Clinical trial registration: clinicaltrials.gov (clinical trial number, NCT01665521). ☆☆ Funding source: This study was funded by the American Heart Association Clinical Research Program. The American Heart Association had no role in the design, analysis, interpretation, or writing of this report. The corresponding author had complete access to all study data and final responsibility for article submission. Use of Research Electronic Data Capture was supported by the Wake Forest Translational Science Institute via a grant from National Center for Catalysis Research (M01 RR007122). ★ None of the authors have any disclosures to report.savings in the HEART Pathway arm compared with the usual care arm of the HEART Pathway study, particularly among low-risk patients.
Methods
This study was a preplanned secondary analysis of patients enrolled in the HEART Pathway trial, a randomized controlled single-center clinical trial funded by the American Heart Association (AHA). The trial enrolled patients with symptoms suggestive of ACS from the ED (of institution name withheld for review) from September 2012 through February 2014. All 282 enrolled participants provided witnessed written informed consent and were randomized to either usual care or the HEART Pathway (1:1 randomization). Eligibility criteria included the provider ordering an electrocardiogram (ECG) and troponin with the primary purpose of evaluating potential ACS in patients 21 years or older. Patients were determined ineligible for the following reasons: new ST-segment elevation at least 1 mm, hypotension, life expectancy less than 1 year, the presence of a noncardiac medical, surgical, or psychiatric illness determined by the provider to require admission, previous enrollment, non-English speaking, and incapacity or unwillingness to consent.
In the usual care arm, care delivery was at the discretion of the provider and not determined by trial protocol; providers were encouraged to follow standards of care per the College of Cardiology Foundation (ACCF)/AHA guidelines [4, 5] . For those participants randomized to the HEART Pathway arm, they were risk stratified by attending ED providers using the HEART score and serial troponin measures at 0 and 3 hours after ED presentation. The HEART score consists of 5 components: history, ECG, age, risk factors, and initial troponin. To calculate a HEART score, first each component is assessed (on a scale of 0-2), and then component scores are summed to produce the final score (Table 1) . A HEART score of 0 to 3 is consistent with a low-risk assessment for MACE within 30 days, whereas a score of at least 4 is consistent with a high-risk assessment [6] [7] [8] [9] . On the basis of the HEART score and serial troponin results, the attending physicians received care recommendations according to the HEART Pathway ( Fig. 1 ). For patients with low-risk HEART scores (HEART score of 0-3) and negative troponin results, the HEART Pathway recommended discharge from the ED without further testing (biomarkers, stress testing, coronary angiography, etc); these patients were encouraged to follow up with their primary care provider.
In patients with a high-risk HEART score (HEART score of ≥4) or any troponin measure above the 99th percentile threshold (regardless of HEART score), the HEART Pathway recommended further evaluation in the hospital or observation unit per ACCF/AHA guidelines [4, 5] . Follow-up was performed at 30 days for all patients via medical record review and telephone interviews. The institutional review committee at (institution name withheld for review) approved this study and subjects gave informed consent to participate in this study before recruitment. Further details regarding the trial have been previously published [3] . For this study, we performed a cost analyses of patients enrolled in the HEART Pathway trial, including prespecified comparisons between the usual care and HEART Pathway arms, high-and low-risk patients as determined by the HEART Score in the HEART Pathway arm, and of high-and low-risk patients by "Thrombolysis In Myocardial Infarction" (TIMI) criteria between the usual care and HEART Pathway arms. We compared index visit cost, cost at 30 days (including the index visit cost), and cardiac-related health care cost at 30 days (including index visit cost) between the 2 treatment arms. Index cost for each patient was based on total facility and professional costs for the index encounter. Cost at 30 days included all inpatient and outpatient facility and professional costs for 30 days after the index encounter, including the index encounter cost, and included all costs (cardiac and non-cardiac-related) during that period. Cardiac-related health care cost at 30 days included the index cost plus any cardiac-related office visits, admissions, or cardiac testing within the follow-up period. Costs were deemed cardiacrelated if they pertained to cardiac-related office, ED, or hospital visits and/or included objective cardiac testing based on blinded review and adjudication by Drs Mahler and Hiestand.
We then broke the 30-day total costs down into individual components based on the specific aims of the parent trial, including the following: cardiac and noncardiac diagnostic testing cost, ED cost, inpatient cost for the index visit (excluding ED cost), and outpatient cost. Cardiac diagnostics included stress testing modalities, echocardiography, computed tomographic angiography, or invasive coronary angiography.
Cost was measured directly, calculated as the sum of hospital and provider cost and measured from the health system perspective, including cost associated with care at the enrolling hospital system and those outside the enrolling system, if applicable. For hospital or clinic cost, itemized patient charges were converted to cost, with 2012 departmental-specific cost/charge ratios used to file cost reports with the Centers for Medicare & Medicaid Services annually. Provider cost was determined by using current procedural terminology codes from each charged service, converting to physician work relative value units with the Centers for Medicare & Medicaid Services physician fee schedule and subsequently converting to dollars with the Medicare conversion factor. For all payers, itemized hospital charges from each participant were converted to cost. This method has been previously reported by our group [10] .
All discrete variables were compared using χ 2 rank-based group means score statistics, and all continuous variables were compared using Spearman rank correlations for the comparison of the 2 treatment arms' baseline characteristics. Cost data differences were evaluated using Mann-Whitney U tests. Medians, 25th and 75th percentiles, means, and 95% confidence intervals were calculated for the observed cost data. We reported median (interquartile range [IQR]) and mean (SD) differences in cost rounded to the nearest dollar, although focus on the median values for the Results section given the skewed, nonparametric distribution of the data, as shown by the IQRs and means. Statistical analysis was performed using SAS 9.4 (Cary, NC).
Results
Cost data were available for 270 of the 282 enrolled patients in the trial; the first 12 patients were enrolled before the most recent electronic medical record at the enrolling institution had been implemented and had unreliable cost data for analysis. Thirty-day follow-up data were available for 100% (270/270) of this group. Baseline characteristics for patients included in this study for both treatment arms are shown in Table 2 . Costs for the index visit and at 30-day follow-up for the 2 treatment arms are shown in Table 3 . The HEART Pathway arm had a statistically significant lower cost (median cost of $1307) per individual compared with the usual care arm (median cost of $1523). Table 4 shows the cost difference between the high-and low-risk HEART Pathway patients in the HEART Pathway arm, illustrating the significantly increased cost for high-risk (median cost of $2349) compared with low-risk patients (median cost of $746). We also evaluated the cost between low-risk (TIMI 0/1) patients in both arms in Table 5 . This table illustrates that use of the HEART Pathway leads to a significant reduction in total cost at 30 days compared with usual care in the low-risk group (median cost of $974 and $1227, respectively).
On analysis of the breakdown of the 30-day total costs between the 2 treatment arms, there was no significant difference in the individual components of the total cost between the groups (Table 6 ). A similar comparison was made for the low-risk (TIMI 0/1) groups in both arms at 30 days, as shown in Table 7 , which showed that there was a significant difference in cardiac diagnostics cost of $118 (P = .04) between these 2 groups.
Discussion
The HEART Pathway is a decision aid tool used to classify patients presenting with undifferentiated chest pain into high and low risk for MACE during the index visit and at 30-day follow-up. Randomized Table 3 Cost comparison between usual care and the HEART Pathway Cost
Usual care (n = 136) HEART Pathway (n = 134) P Table 4 Cost comparison between high-and low-risk patients in the HEART Pathway arm data have shown that use of the HEART Pathway to risk stratify this group significantly decreases objective cardiac testing, increases rates of early discharge, and decreases median length of stay without increasing the risk for adverse events or recurrent evaluations for chest pain [3] . This study adds to the previous literature by showing that use of the HEART Pathway not only increases the efficiency of health care utilization for the evaluation of this patient group but does so at a significant cost savings compared with usual care, most notable in the lowrisk group and driven primarily by lower cardiac diagnostic costs in the HEART Pathway group. The management of patients with chest pain is a common and challenging clinical problem, requiring the clinician to distinguish between those who require urgent management of more serious diagnoses such as ACS and those with more benign entities who do not require admission. Although clinical judgment continues to be paramount in meeting this challenge, new diagnostic modalities have been developed to assist in risk stratification. These include biomarkers of cardiac injury, risk scores, early stress testing, and noninvasive imaging of the heart. Multiple imaging strategies have been investigated to accelerate diagnosis and to provide further risk stratification of patients presenting withy chest pain and no initial evidence of ACS, including myocardial perfusion imaging, computed tomographic coronary angiography, and cardiac magnetic resonance imaging [11] . Miller et al [10] demonstrated that use of cardiac imaging decreased the cost of evaluating high-risk patients presenting with undifferentiated chest pain compared with standard care practices. However, when this same protocol was applied to lower-risk patients, the most cost-effective strategy appeared to be provider-directed testing compared with a mandated specific imaging strategy protocol, which speaks to the paramount importance of the initial clinical evaluation in this group before stress testing or more invasive evaluations [12] .
Despite the increasing use of noninvasive testing in this patient group, the basic clinical tools of history, physical examination, electrocardiography, and biomarker testing (ie, troponin) are currently widely acknowledged to allow for early identification of low-risk patients. The ACCF/AHA guidelines currently recommend that patients at low risk for ACS should undergo routine evaluation using these methods, followed by objective cardiac testing (stress testing or cardiac imaging) [13] . However, the value of objective cardiac testing in all low-risk patients is questionable, especially as cardiac testing for all patients at low risk for ACS is not sustainable from a quality or economic standpoint. Risk assessment using decision aids such as the HEART Pathway mitigates the radiation exposure, exposure to contrast and/or vasodilatory/inotropic stress agents, false-positive rate, and anxiety associated with stress testing low-risk patients, most of whom will not ultimately benefit from the testing. The combination of the primary analyses and this cost analysis illustrate that the HEART Pathway has proven to reliably predict low MACE rates in low-risk patients presenting with undifferentiated chest pain, obviating the need for stress testing, and resulting in improved economic efficiency. In our study, these savings were on average $216 per patient, which on an individual scale, may seem somewhat diminutive. However, when this savings is evaluated on a larger scale from a health systems perspective, this could result in more than $2 billion in savings for the 8 to 10 million patients evaluated in the United States for undifferentiated chest pain on an annual basis. Depending on a hospital or health system's patient population distribution of cardiovascular disease risk factors, this could result in even higher savings for those caring for lower-risk profile groups.
Our study has several limitations. There were missing data on the first 12 patients due to implementation of a new electronic medical record system. Although there is no reason to believe that this would skew the results in a meaningful way based on the results of the randomization seen in Table 2 , there is still the possibility for bias as they were recruited during the initial recruitment stages of the study, which could have had variable adherence to the guidelines in the study protocol. The study is also a single-center study, so the results may not yet be generalizable to other regions.
In conclusion, the HEART Pathway is a decision tool that has been shown to reliably risk stratify patients presenting with undifferentiated chest pain into high and low risk for MACE at 30 days. This risk stratification has been shown to decrease health care utilization in the low-risk population without untoward clinical events. This study illustrates that it decreases the cost of health care delivery to this group as well, especially in the low-risk group. Table 5 Cost comparison between low-risk patients (TIMI 0-1) in the HEART Pathway vs the usual care arms
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